In order to make a report on 90 cases of insomnia treated by the Wei-defensive qi-regulating and brain-strengthening needling technique,as a clinical subject of the multiple center,for assessing the preliminary standardized indications and operating methods and making an initial summary for writing the draft of the technique operation.Methods:By ratio of 1:1,the patients in conformity with the criteria were randomly divided into the experimental group and control group.In the experimental group,45 cases were treated with the Wei-defensive qi-regulating and brain-strengthening needling technique on Baihui (GV 20),Dazhui(GV 14),Shenmai(BL 62),Zhaohai(KI 6),plus ear points.In the control group,45 cases were treated with routine acupuncture on Sishencong(Ex-HN 1),Shenmen (HT 7),Sanyinjiao(SP 6),etc.The therapeutic effects in the two groups were observed and assessed in comparison.Results:The results showed cure in 15 cases.remarkable effect in 27 cases,effect in 42 cases,failure in 6 cases,and the total eriective rate in 94.4% in 90 cases of insomnia.In the three centers,the statistic management was performed based upon PSQI integral and showed significant difference(P＜0.01),and no significant difference among various groups(P＞0.01).Conclusion:The therapeutic effect in the treatment of insomnia by Wei-defensive qi-regulating and brain-strengthening needling technique is better than the control group and the therapeutic effect and methods in various centers are stable.without any deviation.

Objective To investigate the unquanlified screening results of blood donors′ infectious markers in this center ,de-velop a scientific blood screening policy and provide a basis for assessing the efficiency of blood screening reagent .Methods un-quanlified screening results of blood donors′ infectious markers in this center were analyzed from July 2014 to June 2015 ,and the distribution of detection reagents were also detected .Results 120 756 samples were detected in Chongqing blood center ;among 2 854 cases of unquanlified samples ,there were 768 cases of ELISA + /NAT + ,38 cases of NAT + /ELISA - 3 (111 cases NAT were i-dentified as HBV) ;unqualified specimens of anti-TP ,HBsAg ,anti-HIV ,anti-HCV were 895 ,1 012 ,276 and 444 cases respectively ;Double ELISA reagent unqualified rate were 78 .6% ,77 .3% ,30 .8% ,26 .1% respectively .The main unqualified results of NAT were HBV ,the blood donors that were reactive in only HBsAg single reagent of ELISA also reactive for HBV in differential NAT . Conclusion On the condition that comply with laws and operations specification ,the blood screening strategy of selecting once ELISA and once NAT rationally is feasible .

Digital medicine underwent the conversion from "digital human" to digital medical technology and has been widely used in all aspects of clinical medicine in recent 10 years,especially in hilar cholangiocarcinoma (HCCA).It is difficult to accurately evaluate the longitudinal and vertical tumor invasion by preoperative conventional imaging assessment (CT,MRI,etc.) due to the complexity of this operation.Three-dimensional (3D) visualization can see more comprehensively,more clearly and more accurately on the basis of organs and lesions indicated by CT and MRI.Three-dimensional visualization digital medical technology can accurately,intuitively and stereoscopically display the situation of tumor invasion of the adjacent important vessels as well as the variation of vessels.It plays an important role in the aspects of preoperative evaluation,surgical planning,improving the success rate of operation and reducing complications for HCCA.It also transforms the past model of "crossing the river by feeling the stone" to now "crossing the river by watching the stone".Therefore,it is known as the paradigm of translational medicine.

OBJECTIVE To investigate the efficacy and safety of hetrombopag combined with low-dose prednison in the treatment of patients with refractory/recurrent primary immune thrombocytopenia(ITP). METHODS A total of 40 patients with ITP who failed to respond to previous treatment or relapsed in the Department of Hematology of Gansu Provincial People’s Hospital From July 2021 to August 2022 were selected. Used randomized controlled trial research methods, according to the treatment plan, they were divided into observation group and control group, with 20 cases in each group. The control group was treated with low-dose prednison alone. The observation group was combined with hetrombopag treatment on this basis. The efficacy and adverse reactions were compared between the two groups. RESULTS Treatment 6 weeks, patients who's proportion of platelet counts(PLT) reached≥50×109·L−1 and ≥30×109·L−1 in observation group were higher than control group with statistically significant differences in both groups[90%(18/20) vs 50%(10/20), P＝0.006; 90%(18/20) vs 65%(13/20), P＝0.130]; The study also indicated a statistically significant difference in favour of observation group compared with control group in the odds of achieving the outcome of a PLT≥50×109·L−1at least once during 6-week treatment[90%(18/20) vs 55%(11/20), P＝0.147], was more than placebo-treated one. The median time of PLT ≥ 50×109·L−1 for the first time within 6 weeks of treatment in the observation group was 3 weeks, which was the same as that in the control group. After 6 weeks of treatment, the median platelet count in the observation group was higher than that in the control group[97.50(58.25−166.75)×109·L−1 vs 45.50(13.25−82.50)×109·L−1 , P<0.05]. The median PLT count in the observation group was higher than that in the control group at week 1−6 after treatment, and the curative effect was significant. The two groups of patients tolerated the regimen well, and the degree of adverse reactions was mild, which improved quickly after symptomatic treatment. CONCLUSION Hetrombopag combined with low-dose prednison has a high effective rate in the treatment of refractory/recurrent ITP, which is better than that of single use, and the adverse reactions are tolerable, so it can be widely used in clinical practice.

Raman spectroscopy, amplified by surface-enhanced Raman scattering (SERS) nanoparticles, can provide an imaging modality due to its high molecular specificity, high sensitivity, and negligible autofluorescence. The basis, composition, and methodologies developed for SERS nanoparticles are herein described. The research hotspots that are the focus in this paper are tumor imaging-guided theranostics and biosensing. The next breakthrough may be the development of biocompatible SERS nanoparticles and spectroscopic devices for clinical applications.